The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients

Launched by BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY, DHAKA, BANGLADESH · May 8, 2021

Keywords

ClinConnect Summary

The newly emerged Coronavirus disease 2019 (COVID-19), which was first identified in Wuhan, China, has swept through 219 countries, killing a staggering number of people. The World Health Organization (WHO) has declared the deadly outbreak a pandemic, with far-reaching consequences for all people. According to WHO reports, the number of deaths had risen to 3,155,168by March 30, 2021, out of 149,910,744 confirmed cases.

The pathogen for COVID-19 has been described as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new beta-coronavirus. Following the outbreaks of the seve...

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Confirmed COVID-19 patients by RT-PCR
• • Clinically suspected COVID-19 patients
• • Age \> 18 years
• • Patients requiring oxygen at least\> 5L/min up to 15 L/min (by FM/ NRM)to maintain saturation \>92% to 96%
• • NOTE: Clinically suspected COVID-19 = fever (Temperature \>37.8 Degree Celsius) + respiratory symptoms + Radiological evidences Exclusion criteria
• • Multi-organ failure
• • Severe ARDS (requiring HFNC orventilatory support on presentation in the form ofinvasive or non-invasive ventilation)
• • Septic Shock
• • Severe liver disease
• • Acute Heart Failure
• • Acute Kidney Injury (where GFR\< 15 and plasma-sulfamethoxazoleconcentration cannot be monitored)
• • Drug allergy/intolerance to co-trimoxazole / Sulphar sensitivity
• • Pregnancy